MGNX:NASDAQMacroGenics, Inc. analysis

MacroGenics trades at $4.13, comfortably above its 20‑day ($4.11), 50‑day ($3.71) and 200‑day ($2.33) simple moving averages, suggesting a bullish price bias despite a bearish MACD histogram and a decreasing volume trend. The stock’s RSI of 55 indicates neutral momentum, while a 90% 30‑day volatility and a beta of 1.38 underscore heightened price swings typical of biotech firms.
The company’s fundamentals are a mixed bag: revenue surged 57.5% YoY to $157 M, yet margins remain deep in the red and earnings are negative, driving a PE of –2.9 and a P/B of 12.4. A recent $200 M cash infusion from a royalty monetization deal and the sale of its manufacturing unit extends the cash runway to 2028, and the DCF fair value of $7.58 implies a 63% upside, aligning with the “Extreme Greed” sentiment in the fear‑greed index.